Pacific Biosciences of California (PACB) Stock Forecast, Price & News

9 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Pacific Biosciences of California in the last year. There are currently 4 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" PACB shares.
View PACB analyst ratings or view top-rated stocks.

9 brokerages have issued 12-month price targets for Pacific Biosciences of California's stock. Their PACB share price forecasts range from $9.00 to $17.00. On average, they predict the company's stock price to reach $13.10 in the next twelve months. This suggests a possible upside of 62.7% from the stock's current price.
View analysts price targets for PACB or view top-rated stocks among Wall Street analysts.

Pacific Biosciences of California's stock was trading at $8.18 at the beginning of 2023. Since then, PACB stock has decreased by 1.6% and is now trading at $8.05.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Monday, November 6th 2023.
View our PACB earnings forecast.

Pacific Biosciences of California, Inc. (NASDAQ:PACB) posted its quarterly earnings results on Wednesday, August, 2nd. The biotechnology company reported ($0.26) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.32) by $0.06. The biotechnology company had revenue of $47.57 million for the quarter, compared to analyst estimates of $40.12 million. Pacific Biosciences of California had a negative trailing twelve-month return on equity of 46.47% and a negative net margin of 218.43%. Pacific Biosciences of California's revenue was up 34.1% on a year-over-year basis. During the same period in the prior year, the firm posted ($0.34) earnings per share.

ETFs with the largest weight of Pacific Biosciences of California (NASDAQ:PACB) stock in their portfolio include ARK Genomic Revolution ETF (ARKG), Global X Telemedicine & Digital Health ETF (EDOC), Global X Genomics & Biotechnology ETF (GNOM), Invesco Biotechnology & Genome ETF (PBE), AXS Green Alpha ETF (NXTE), ARK Innovation ETF (ARKK), Invesco Dorsey Wright Healthcare Momentum ETF (PTH) and BNY Mellon Innovators ETF (BKIV).

2 employees have rated Pacific Biosciences of California Chief Executive Officer Christian Henry on Glassdoor.com. Christian Henry has an approval rating of 100% among the company's employees. This puts Christian Henry in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other Pacific Biosciences of California investors own include Pfizer (PFE), Gilead Sciences (GILD), Illumina (ILMN), Novavax (NVAX), Advanced Micro Devices (AMD), AT&T (T), Inovio Pharmaceuticals (INO), NVIDIA (NVDA), Invitae (NVTA) and Tesla (TSLA).

Pacific Biosciences of California trades on the NASDAQ under the ticker symbol "PACB."

Shares of PACB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of PACB stock can currently be purchased for approximately $8.05.

Pacific Biosciences of California (NASDAQ:PACB) has a market capitalization of $2.02 billion and generates $128.30 million in revenue each year. The biotechnology company earns $-314,250,000.00 in net income (profit) each year or ($1.35) on an earnings per share basis.

The company employs 769 workers across the globe.

Pacific Biosciences of California's mailing address is 1305 O`BRIEN DRIVE, MENLO PARK CA, 94025. The official website for the company is www.pacb.com. The biotechnology company can be reached via phone at (650) 521-8000, via email at ir@pacb.com, or via fax at 302-636-5454.